TERAPIA COMBINADA COM ROSUVASTATINA E EZETIMIBA (TREZETE) NA DISLIPIDEMIA DE MUITO ALTO RISCO CARDIOVASCULAR: EVIDÊNCIAS DE EFICÁCIA E IMPACTO CLÍNICO
DOI:
https://doi.org/10.56238/levv16n54-030Palavras-chave:
Dislipidemia, Rosuvastatina, Ezetimiba, Terapia Combinada, Risco CardiovascularResumo
A dislipidemia de muito alto risco cardiovascular exige estratégias eficazes e seguras para redução intensiva do LDL-C. Esta revisão integrativa analisou estudos publicados entre 2015 e 2025 sobre a combinação rosuvastatina/ezetimiba em contextos de alto risco cardiovascular. A busca foi realizada nas bases PubMed, Scopus, Web of Science, SciELO, LILACS e ScienceDirect. A associação demonstrou redução adicional de LDL-C de até 25% em relação à monoterapia, com perfil de segurança favorável e maior adesão em formulações de dose fixa. Resultados consistentes foram observados em subgrupos como diabéticos, idosos e pacientes com DAC. As principais limitações incluem o tempo de seguimento reduzido e escassez de estudos comparativos com novas terapias hipolipemiantes. Conclui-se que a combinação rosuvastatina/ezetimiba é uma alternativa eficaz, segura e aplicável em populações de risco muito alto, devendo ser considerada como primeira escolha em cenários de prevenção cardiovascular intensiva.
Downloads
Referências
AKYE, L. N.; KIRK, G. D.; KWON, S. Y. Rosuvastatin and Ezetimibe for Lipid Control in Dyslipidemia. American Journal of Preventive Cardiology, v. 10, n. 2, p. 81–88, 2025. DOI: https://doi.org/10.1016/j.ajpc.2025.07.015.
BAK, S. H. et al. Efficacy and safety of low-dose rosuvastatin/ezetimibe for dyslipidemia in patients with rheumatoid arthritis or osteoarthritis. Medicine, v. 104, n. 40, p. e33440, 2025. Disponível em: https://journals.lww.com/md-journal/fulltext/2025/07040/efficacy_and_safety_of_low_dose.101.aspx.
BRIE, D. M. et al. Dyslipidemia treatment in patients with acute coronary syndrome: is it time to move to combination therapy? Journal of Clinical Medicine, v. 14, n. 18, p. 6445, 2025. DOI: https://doi.org/10.3390/jcm14186445.
DODULÍK, J. et al. Triple non-statin therapy with ezetimibe, inclisiran, and bempedoic acid in patients with genetically confirmed statin-induced rhabdomyolysis: a dual case report. Pharmaceuticals, v. 18, n. 6, p. 818, 2025. DOI: https://doi.org/10.3390/ph18060818.
FERRI, N. Do anti-PCSK9 monoclonal antibodies have pleiotropic effects? JACC: Basic to Translational Science, v. 10, n. 5, p. 456–462, 2025. DOI: https://doi.org/10.1016/j.jacbts.2025.04.005.
FILINA, Z. V.; LITYUSHKINA, M. I.; ALAYEVA, Z. G. Analysis of methods for normalizing lipid profile and blood pressure in patients with chronic coronary syndromes. Medicine and Biotechnology, v. 15, n. 2, p. 78–84, 2025.
HUMMADI, A. et al. Whole exome sequencing identifies concurrent LDLR and ABCG8 mutations in a Saudi family with familial hypercholesterolemia and sitosterolemia. Frontiers in Genetics, v. 16, p. 1679594, 2025. DOI: https://doi.org/10.3389/fgene.2025.1679594.
KIM, H. L. et al. Real-world effectiveness of rosuvastatin–ezetimibe single pill (Rovazet®) in Korean dyslipidemia patients. Journal of Clinical Medicine, v. 14, n. 15, p. 5480, 2025. DOI: https://doi.org/10.3390/jcm14155480.
LIU, Y. et al. Comparative lipid-lowering effects of statin monotherapy versus statin plus ezetimibe: a meta-analysis. Journal of Clinical Lipidology, v. 15, n. 1, p. 45–52, 2023.
MATHIOUDAKIS, K. et al. Prevalence, incidence, and patterns of lipid-lowering treatment in Greece based on real-world nationwide data on 8,535,780 adults. Hellenic Journal of Cardiology, v. 66, n. 3, p. 213–221, 2025. DOI: https://doi.org/10.1016/j.hjc.2025.04.003.
PRIANI, S. E. et al. Formulation strategies for ezetimibe and its combinations: advancing biopharmaceutical and therapeutic potential. Drug Design, Development and Therapy, v. 19, p. 1357–1369, 2025. DOI: https://doi.org/10.2147/DDDT.S550340.
PARK, S. et al. Efficacy and safety of quadruple-drug fixed-dose single-pill combination therapy for hypertension and dyslipidemia: a prospective, multicenter study. Clinical Therapeutics, v. 47, n. 7, p. 1054–1065, 2025.
PERREGAUX, J. F.; GALLO, A. From histiocytosis to sitosterolemia: a case report. Atherosclerosis, v. 371, p. 122–125, 2025.
VARGHESE, A.; HEGELE, R. A. SAT-248 A case series of heterozygous familial hypercholesterolemia with PCSK9 inhibitor failure. Journal of the Endocrine Society, v. 9, suplemento 1, p. bvaf149.803, 2025.
WEI, H. et al. Effectiveness of fixed-dose rosuvastatin and ezetimibe in managing high cardiovascular risk dyslipidemia patients: a real-world observational study. Current Medical Research and Opinion, v. 39, n. 8, p. 1234–1242, 2024.
